Securities and Exchange Commission
                            Washington, D.C. 20549

                           SCHEDULE 14A INFORMATION

                  Proxy Statement Pursuant to Section 14(A)
                    of the Securities Exchange Act of 1934

                         Filed by the Registrant [ ]
                 Filed by a Party other than the Registrant [X]

                         Check the appropriate box:
                     [ ] Preliminary Proxy Statement
                     [ ] Definitive Proxy Statement
                     [X] Definitive Additional Materials
          [ ] Soliciting Material Pursuant to Section 240.14a-11(c)
                             or Section 240.14a-12


                              Circon Corporation
                 (Name of Registrant as Specified in its Charter)


                      United States Surgical Corporation
                    (Name of Person Filing Proxy Statement)

                          ----------------------------

          Payment of Filing Fee (Check the appropriate box):

          [X]  No fee required.

          [ ]  Fee computed on table below per Exchange Act Rules
               14a-6(i)(4) and 0-11.

               (1) Title of each class of securities to which
                   transaction applies:  N/A

               (2) Aggregate number of securities to which
                   transaction applies: N/A

               (3) Per unit price or other underlying value of
                   transaction computed pursuant to Exchange Act Rule
                   0-11 (Set forth the amount on which the filing fee
                   is calculated and state how it was determined): N/A

               (4) Proposed maximum aggregate value of transaction:
                   N/A

               (5) Total fee paid: N/A

          [ ]  Fee previously paid with preliminary materials.

          [ ]  Check box if any part of the fee is offset as
               provided by Exchange Act Rule 0-11(a)(2) and
               identify the filing for which the offsetting fee was
               paid previously.  Identify the previous filing by
               registration statement number, or the Form or
               Schedule and the date of its filing.

               (1) Amount previously paid: 

               (2) Form, Schedule or Registration Statement Number:

               (3) Filing Party: 

               (4) Date Filed: 






                       [U.S. Surgical Letterhead] 

      FOR IMMEDIATE RELEASE:  October 1, 1997

 INVESTOR CONTACT:        U.S. SURGICAL HOME PAGE      MEDIA CONTACT:
 Marianne Scipione             http://www.ussurg.com   Steve Rose
 Vice President                                        Director
 Corporate Communications                              Media Relations
 (203) 845-1404                                        (203) 845-1732
 marianne.scipione@ussurg.com                          steve.rose@ussurg.com

                   ISS RECOMMENDS VOTE FOR U.S. SURGICAL
                      SLATE AT CIRCON ANNUAL MEETING

           NORWALK, Conn. United States Surgical Corporation
      (NYSE:USS) announced today that Institutional Shareholder
      Services (ISS), one of the nation's leading shareholder
      advisory organizations specializing in proxy analysis, has
      recommended that shareholders of Circon Corporation
      (NASDAQ:CCON) vote on the BLUE proxy card FOR USS' two
      nominees to the Circon Board and FOR USS' proposal to seek
      the prompt sale of Circon .  The Circon Annual Meeting will
      be held Monday, October 6, 1997, at 9:00 a.m. in Santa
      Barbara, California.

           "We are very pleased with the ISS report," said Leon C.
      Hirsch, Chairman and Chief Executive Officer of USS.   "ISS
      supports USS' attempt to stop the Circon Board's 'defiance of
      the wishes of shareholders,' stating 'The shareholders have
      spoken, but Circon is not listening.'"

                United States Surgical Corporation is a diversified
      surgical products company specializing in minimally invasive
      technologies that improve patient care and lower health
      costs.